400 related articles for article (PubMed ID: 16828940)
21. Trivalent Human Papillomavirus (HPV) VLP vaccine covering HPV type 58 can elicit high level of humoral immunity but also induce immune interference among component types.
Zhang T; Xu Y; Qiao L; Wang Y; Wu X; Fan D; Peng Q; Xu X
Vaccine; 2010 Apr; 28(19):3479-87. PubMed ID: 20211219
[TBL] [Abstract][Full Text] [Related]
22. Incorporation of RG1 epitope concatemers into a self-adjuvanting Flagellin-L2 vaccine broaden durable protection against cutaneous challenge with diverse human papillomavirus genotypes.
Kalnin K; Chivukula S; Tibbitts T; Yan Y; Stegalkina S; Shen L; Cieszynski J; Costa V; Sabharwal R; Anderson SF; Christensen N; Jagu S; Roden RBS; Kleanthous H
Vaccine; 2017 Sep; 35(37):4942-4951. PubMed ID: 28778613
[TBL] [Abstract][Full Text] [Related]
23. Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: end-of-study analysis of a Phase III randomized trial.
Einstein MH; Takacs P; Chatterjee A; Sperling RS; Chakhtoura N; Blatter MM; Lalezari J; David MP; Lin L; Struyf F; Dubin G;
Hum Vaccin Immunother; 2014; 10(12):3435-45. PubMed ID: 25483701
[TBL] [Abstract][Full Text] [Related]
24. B lymphocyte activation by human papillomavirus-like particles directly induces Ig class switch recombination via TLR4-MyD88.
Yang R; Murillo FM; Delannoy MJ; Blosser RL; Yutzy WH; Uematsu S; Takeda K; Akira S; Viscidi RP; Roden RB
J Immunol; 2005 Jun; 174(12):7912-9. PubMed ID: 15944297
[TBL] [Abstract][Full Text] [Related]
25. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant.
Pedersen C; Petaja T; Strauss G; Rumke HC; Poder A; Richardus JH; Spiessens B; Descamps D; Hardt K; Lehtinen M; Dubin G;
J Adolesc Health; 2007 Jun; 40(6):564-71. PubMed ID: 17531764
[TBL] [Abstract][Full Text] [Related]
26. Enhanced mucosal and systemic immunogenicity of human papillomavirus-like particles encapsidating interleukin-2 gene adjuvant.
Oh YK; Sohn T; Park JS; Kang MJ; Choi HG; Kim JA; Kim WK; Ko JJ; Kim CK
Virology; 2004 Oct; 328(2):266-73. PubMed ID: 15464846
[TBL] [Abstract][Full Text] [Related]
27. Co-vaccination with adeno-associated virus vectors encoding human papillomavirus 16 L1 proteins and adenovirus encoding murine GM-CSF can elicit strong and prolonged neutralizing antibody.
Liu DW; Chang JL; Tsao YP; Huang CW; Kuo SW; Chen SL
Int J Cancer; 2005 Jan; 113(1):93-100. PubMed ID: 15386434
[TBL] [Abstract][Full Text] [Related]
28. Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2.
Tumban E; Muttil P; Escobar CA; Peabody J; Wafula D; Peabody DS; Chackerian B
Vaccine; 2015 Jun; 33(29):3346-53. PubMed ID: 26003490
[TBL] [Abstract][Full Text] [Related]
29. Developments in L2-based human papillomavirus (HPV) vaccines.
Schellenbacher C; Roden RBS; Kirnbauer R
Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
[TBL] [Abstract][Full Text] [Related]
30. Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice.
Ohlschläger P; Osen W; Dell K; Faath S; Garcea RL; Jochmus I; Müller M; Pawlita M; Schäfer K; Sehr P; Staib C; Sutter G; Gissmann L
J Virol; 2003 Apr; 77(8):4635-45. PubMed ID: 12663770
[TBL] [Abstract][Full Text] [Related]
31. Improvement of RG1-VLP vaccine performance in BALB/c mice by substitution of alhydrogel with the next generation polyphosphazene adjuvant PCEP.
Valencia SM; Zacharia A; Marin A; Matthews RL; Wu CK; Myers B; Sanders C; Difilippantonio S; Kirnbauer R; Roden RB; Pinto LA; Shoemaker RH; Andrianov AK; Marshall JD
Hum Vaccin Immunother; 2021 Aug; 17(8):2748-2761. PubMed ID: 33573433
[TBL] [Abstract][Full Text] [Related]
32. Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles.
Pinto LA; Edwards J; Castle PE; Harro CD; Lowy DR; Schiller JT; Wallace D; Kopp W; Adelsberger JW; Baseler MW; Berzofsky JA; Hildesheim A
J Infect Dis; 2003 Jul; 188(2):327-38. PubMed ID: 12854090
[TBL] [Abstract][Full Text] [Related]
33. Relationship between Humoral Immune Responses against HPV16, HPV18, HPV31 and HPV45 in 12-15 Year Old Girls Receiving Cervarix® or Gardasil® Vaccine.
Godi A; Bissett SL; Miller E; Beddows S
PLoS One; 2015; 10(10):e0140926. PubMed ID: 26495976
[TBL] [Abstract][Full Text] [Related]
34. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and 4vHPV vaccine administered according to two- or three-dose schedules in girls aged 9-14 years: Results to month 36 from a randomized trial.
Leung TF; Liu AP; Lim FS; Thollot F; Oh HML; Lee BW; Rombo L; Tan NC; Rouzier R; De Simoni S; Suryakiran P; Hezareh M; Thomas F; Folschweiller N; Struyf F
Vaccine; 2018 Jan; 36(1):98-106. PubMed ID: 29174109
[TBL] [Abstract][Full Text] [Related]
35. Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model.
Greenstone HL; Nieland JD; de Visser KE; De Bruijn ML; Kirnbauer R; Roden RB; Lowy DR; Kast WM; Schiller JT
Proc Natl Acad Sci U S A; 1998 Feb; 95(4):1800-5. PubMed ID: 9465097
[TBL] [Abstract][Full Text] [Related]
36. RG2-VLP: a Vaccine Designed to Broadly Protect against Anogenital and Skin Human Papillomaviruses Causing Human Cancer.
Olczak P; Matsui K; Wong M; Alvarez J; Lambert P; Christensen ND; Hu J; Huber B; Kirnbauer R; Wang JW; Roden RBS
J Virol; 2022 Jul; 96(13):e0056622. PubMed ID: 35703545
[TBL] [Abstract][Full Text] [Related]
37. Comparison of human papillomavirus type 16 L1 chimeric virus-like particles versus L1/L2 chimeric virus-like particles in tumor prevention.
Wakabayashi MT; Da Silva DM; Potkul RK; Kast WM
Intervirology; 2002; 45(4-6):300-7. PubMed ID: 12566713
[TBL] [Abstract][Full Text] [Related]
38. Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines.
Schellenbacher C; Roden R; Kirnbauer R
J Virol; 2009 Oct; 83(19):10085-95. PubMed ID: 19640991
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial.
Harper DM; Franco EL; Wheeler C; Ferris DG; Jenkins D; Schuind A; Zahaf T; Innis B; Naud P; De Carvalho NS; Roteli-Martins CM; Teixeira J; Blatter MM; Korn AP; Quint W; Dubin G;
Lancet; 2004 Nov 13-19; 364(9447):1757-65. PubMed ID: 15541448
[TBL] [Abstract][Full Text] [Related]
40. Pre-clinical immunogenicity of human papillomavirus alpha-7 and alpha-9 major capsid proteins.
Bissett SL; Mattiuzzo G; Draper E; Godi A; Wilkinson DE; Minor P; Page M; Beddows S
Vaccine; 2014 Nov; 32(48):6548-55. PubMed ID: 25203446
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]